Cullinan Therapeutics (CGEM) Expected to Announce Quarterly Earnings on Thursday

Key Points

• Cullinan Therapeutics is expected to report Q3 2026 earnings before the market opens on November 5, with analysts forecasting a loss of $0.84 per share and revenue of approximately $2 million. The conference call is scheduled for November 6 at 9:30 a.m. ET.
• The company reported an adjusted loss of $0.81 per share in the prior quarter, narrowly missing expectations. Analysts project full-year and next-year losses of $3.06 and $2.43 per share, respectively.
• Wall Street’s overall view is moderately bullish, with an average price target of $33.86 versus the stock’s recent $15.56 price, although analyst opinions range from strong buy to sell. Shares have traded between $6.73 and $23.19 over the past year.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) is expected to be posting its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($0.8435) per share and revenue of $2.00 million for the quarter. Investors can find conference call details on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.01). On average, analysts expect Cullinan Therapeutics to post ($3.06) EPS for the current fiscal year and ($2.43) EPS for the next fiscal year.

Cullinan Therapeutics Stock Up 4.9%

Shares of NASDAQ CGEM opened at $15.56 on Thursday. The firm has a 50-day simple moving average of $18.17 and a 200-day simple moving average of $15.73. The stock has a market capitalization of $1.00 billion, a price-to-earnings ratio of -5.02 and a beta of -0.05. Cullinan Therapeutics has a 52 week low of $6.73 and a 52 week high of $23.19.

Insider Activity

In related news, insider Jennifer Michaelson sold 8,000 shares of the firm's stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $21.57, for a total transaction of $172,560.00. Following the completion of the sale, the insider directly owned 158,844 shares in the company, valued at approximately $3,426,265.08. This trade represents a 4.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.60% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on CGEM shares. HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Cullinan Therapeutics in a research report on Friday, October 2nd. TD Cowen raised shares of Cullinan Therapeutics to a "strong-buy" rating in a research note on Monday, August 24th. Wall Street Zen downgraded shares of Cullinan Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, October 24th. BTIG Research increased their price objective on shares of Cullinan Therapeutics from $40.00 to $41.00 and gave the company a "buy" rating in a report on Wednesday. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Cullinan Therapeutics in a research note on Friday, October 2nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, Cullinan Therapeutics has an average rating of "Moderate Buy" and an average price target of $33.86.

About Cullinan Therapeutics

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer. The company builds a portfolio of targeted therapies and immune-modulating treatments designed to address significant unmet needs across hematologic malignancies and solid tumors.

Its development programs include investigational antibody-based therapies and other biologic approaches intended to selectively target cancer cells or activate the immune system. Among its programs are CLN-619, an antibody directed at the MICA and MICB proteins, CLN-418, an immune-activating bispecific molecule, and CLN-049, an investigational treatment designed to engage FLT3 and FLT3 ligand in certain blood cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.